Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)
Key facts
- Where
- Shanghai, ChinaSee the site
- Phase
- Phase 2
Where in China
- Ruijin Hospital, Shanghai Jiao Tong University School of MedicineShanghai, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ruijin Hospital
- Trial code
- NCT06549335
- Record updated
- 15 October 2024
- Original description
This is a prospective, multiple-centers, open-label, single-arm clinical study designed to evaluate the efficacy and safety of Zanubrutinib, Obinutuzumab, and Lenalidomide (ZGR) in high-risk treatment-naive patients with follicular lymphomasRead full original descriptionShow less
The Efficacy and Safety of Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) Regimen in High-risk Treatment-naive Patients with Follicular Lymphoma
This is a prospective, multiple-centers, open-label, single-arm clinical study designed to evaluate the efficacy and safety of Zanubrutinib, Obinutuzumab, and Lenalidomide (ZGR) in high-risk treatment-naive patients with follicular lymphomas
Inclusion: Pathologically confirmed CD20 positive follicular lymphoma grade 1, 2, or 3A based on 2016 WHO classification; Treatment naive; Age ≥ 18 years; Indications for treatment confirmed; Identified as high-risk group by Follicular Lymphoma International Prognostic Index 2 (FLIPI2) at enrollment; Must has measurable lesion in CT or PET-CT prior to treatment; Considered suitable for ZGR regimens; Informed consented.
Exclusion: Any drug contraindication in the treatment plan; HBsAg positive and / or HBcAb positive with HBV DNA titer; HCV antibody positive with HCV-RNA; or HIV positive; Transformed follicular lymphoma or 3B follicular lymphoma; Pregnant or lactating women; Patients judged by other researchers to be unsuitable for inclusion in the study.